Theoretical considerations on quantitative prediction of drug-drug interactions.

The prediction of drug-drug interactions (DDIs) associated with change in clearance for metabolism is reviewed, particularly focusing on pharmacokinetic theories for prediction based on in vitro and in vivo observation. First, there is discussion about how quantitative determination of the contribution of major clearance pathways is fundamental for the accurate prediction of DDIs. Secondly, the concentrations of causative drugs at sites of interactions are discussed. Although DDIs have been predicted from in vitro pharmacokinetic parameters based on predicted hepatic unbound concentrations of inhibitors and inducers, there are noticeable discrepancies between predicted and observed magnitudes of these DDIs. To solve these issues, a method for the prediction of unbound hepatic concentration is proposed based on theoretical considerations. Finally, a pharmacokinetic model to describe the intestinal first pass metabolism is considered, particularly focusing on the importance of the Q(gut) model. Although this Q(gut) model was proposed as an empirical model, theoretical considerations suggest that the model is regarded as a physiologically-based pharmacokinetic model that can predict significance of intestinal DDIs. Theoretical considerations proposed in the present article may be helpful for future analysis of DDIs.

[1]  B. Faller Artificial membrane assays to assess permeability. , 2008, Current drug metabolism.

[2]  J. Kolars,et al.  First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.

[3]  Magang Shou,et al.  Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. , 2005, Current opinion in drug discovery & development.

[4]  Aleksandra Galetin,et al.  Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. , 2007, Current drug metabolism.

[5]  Alex Avdeef,et al.  The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.

[6]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[7]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[8]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[9]  J. Dressman,et al.  Cytochrome P450-mediated metabolism in the human gut wall. , 2009, The Journal of pharmacy and pharmacology.

[10]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[11]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[12]  Amin Rostami-Hodjegan,et al.  Cytochrome P450 3A expression and activity in the human small intestine , 2004, Clinical pharmacology and therapeutics.

[13]  Barry Press,et al.  Permeability for intestinal absorption: Caco-2 assay and related issues. , 2008, Current drug metabolism.

[14]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  A. Galetin,et al.  Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.

[16]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[17]  M. Rowland,et al.  Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models , 1983, The Journal of pharmacy and pharmacology.

[18]  Chuang Lu,et al.  RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB , 2005, Drug Metabolism and Disposition.

[19]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[20]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[21]  R. Obach,et al.  Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[23]  Kiyomi Ito,et al.  CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[25]  C. Crespi Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[26]  W. Hayton,et al.  Dosage Regimen Adjustments in Renal Impairment , 1973 .

[27]  Kaoru Kobayashi,et al.  Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[28]  A. Nafziger,et al.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.

[29]  Kiyomi Ito,et al.  IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM , 2005, Drug Metabolism and Disposition.

[30]  R. V. van Breemen,et al.  Caco-2 cell permeability assays to measure drug absorption , 2005, Expert opinion on drug metabolism & toxicology.

[31]  A. Tsuji Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[32]  Aleksandra Galetin,et al.  Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.

[33]  Kazutaka Higaki,et al.  Gastrointestinal transit and drug absorption. , 2000, Biological & pharmaceutical bulletin.

[34]  H. Kusuhara,et al.  The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.

[35]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[36]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[37]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[38]  R. Bergstrand,et al.  Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine — and its potential clinical relevance , 2004, European Journal of Clinical Pharmacology.

[39]  Ken-Ichi Fujita FOOD-DRUG INTERACTIONS VIA HUMAN CYTOCHROME P450 3A (CYP3A) , 2004, Drug metabolism and drug interactions.

[40]  S. Krähenbühl,et al.  Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.

[41]  Richard Svensson,et al.  Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. , 2006, Pharmacological reports : PR.

[42]  Y. Sugiyama,et al.  A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling , 2009, Clinical pharmacokinetics.

[43]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[44]  Akihiro Hisaka,et al.  General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs , 2007, Clinical pharmacokinetics.

[45]  Shiew-Mei Huang,et al.  Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus , 2001, Pharmaceutical Research.

[46]  Namandjé N. Bumpus,et al.  Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. , 2008, Chemical research in toxicology.

[47]  Bertram Pitt,et al.  Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.

[48]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[49]  Akihiro Hisaka,et al.  General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information , 2008, Clinical pharmacokinetics.

[50]  A. Takagi,et al.  [Drug-drug interaction of antifungal drugs]. , 2005, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[51]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[52]  M. Fromm,et al.  In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions , 2009 .

[53]  G. Caldwell,et al.  Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. , 2001, Current topics in medicinal chemistry.

[54]  R. Riley,et al.  Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[55]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[56]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[57]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[58]  M. Kato,et al.  Intestinal first-pass metabolism of CYP3A4 substrates. , 2008, Drug metabolism and pharmacokinetics.

[59]  Kiyomi Ito,et al.  Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. , 2004, British journal of clinical pharmacology.

[60]  Stephen Fowler,et al.  In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions , 2008, The AAPS Journal.

[61]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[62]  Robert J Riley,et al.  Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[63]  Jörg Lippert,et al.  From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.

[64]  H. Okuda,et al.  Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[65]  A. Y. Lu,et al.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[66]  Akihiro Hisaka,et al.  Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. , 2010, Pharmacology & therapeutics.

[67]  Aleksandra Galetin,et al.  Prediction of In Vivo Drug-Drug Interactions from In Vitro Data , 2006, Clinical pharmacokinetics.

[68]  W. Charman,et al.  The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.

[69]  R. Schlienger,et al.  Potential drug–drug interactions in the medication of medical patients at hospital discharge , 2003, European Journal of Clinical Pharmacology.